CN216496772U - Newborn blood exchange system - Google Patents
Newborn blood exchange system Download PDFInfo
- Publication number
- CN216496772U CN216496772U CN202120171848.6U CN202120171848U CN216496772U CN 216496772 U CN216496772 U CN 216496772U CN 202120171848 U CN202120171848 U CN 202120171848U CN 216496772 U CN216496772 U CN 216496772U
- Authority
- CN
- China
- Prior art keywords
- pipeline
- blood
- pump
- blood pump
- exchange system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 140
- 239000008280 blood Substances 0.000 title claims abstract description 140
- 229920000669 heparin Polymers 0.000 claims abstract description 18
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims abstract description 18
- 229960001008 heparin sodium Drugs 0.000 claims abstract description 18
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 17
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 17
- 238000002347 injection Methods 0.000 claims abstract description 13
- 239000007924 injection Substances 0.000 claims abstract description 13
- 210000003462 vein Anatomy 0.000 claims abstract description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000741 silica gel Substances 0.000 claims abstract description 6
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 6
- 238000012423 maintenance Methods 0.000 claims abstract description 5
- 238000005086 pumping Methods 0.000 claims abstract description 5
- 238000012544 monitoring process Methods 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 7
- 210000001367 artery Anatomy 0.000 claims description 6
- 239000002699 waste material Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 5
- 239000012530 fluid Substances 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 210000002381 plasma Anatomy 0.000 description 11
- 230000037361 pathway Effects 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 206010023126 Jaundice Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000021130 Bilirubin encephalopathy Diseases 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000006663 kernicterus Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010023138 Jaundice neonatal Diseases 0.000 description 1
- 201000006346 Neonatal Jaundice Diseases 0.000 description 1
- 241000083879 Polyommatus icarus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000442 meristematic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Images
Landscapes
- External Artificial Organs (AREA)
Abstract
The utility model discloses a newborn blood exchange system, which comprises a blood conveying pipeline, a blood pumping pipeline and a control display unit, wherein the blood conveying pipeline is connected with the blood pumping pipeline; the blood conveying pipeline comprises a first pipeline for conveying whole blood and a second pipeline for conveying plasma, a first blood pump is arranged in the first pipeline, and a second blood pump is arranged in the second pipeline; the blood drawing pipeline comprises a third pipeline, a silica gel blood collection port, a heparin sodium anticoagulant injection port and a third blood pump are sequentially arranged in the third pipeline, and the heparin sodium anticoagulant injection port is communicated to a first micro pump for injecting heparin sodium anticoagulant through a fourth pipeline; a second micro pump for infusing a maintenance fluid into a second vein is also included. The utility model can integrate the equipment used in the process of changing blood for the newborn into one system, realizes the automation of the process of changing blood, reduces the manpower consumption, reduces the material cost and reduces the risk of blood infection in the process of detecting blood specimens.
Description
Technical Field
The utility model relates to the technical field of medical equipment, in particular to a newborn blood exchange system.
Background
Neonatal jaundice is one of the common diseases in clinic, namely, meristematic jaundice and pathological jaundice, under the condition of pathological jaundice, a series of complications can be caused by too fast or too high neonatal bilirubin level, and a serious infant has the risk of bilirubin encephalopathy, so that the serious infant needs to be hospitalized for manual intervention, namely, a common blue light irradiation therapy, albumin infusion, eating of related traditional Chinese medicines and the like. However, if the bilirubin level is extremely high, the conventional method cannot effectively reduce the bilirubin level, and the infant patient needs to be treated for a blood exchange.
The hemorrhaging treatment is one of important treatment measures for clinically treating the children with hyperbilirubinemia, and the timely and efficient hemorrhaging treatment has important significance for preventing the generation of bilirubin encephalopathy of the newborn. However, at present, no complete equipment is available for clinical use in clinic, manual operation is adopted in many cases, and the automation degree is low. Firstly, a unit with better conditions can use a blood transfusion pump at a blood transfusion end, but no related equipment and materials are available at an arterial blood drawing end, most of the units manually use an injector to draw blood, so that the labor is consumed, and the blood drawing speed cannot be guaranteed; secondly, in the whole operation process, a medical staff is required to continuously switch the whole blood infusion and the blood plasma infusion; thirdly, the whole blood changing operation needs to detect the blood specimen of the infant for many times, the risk of infection is increased when the artery interface is disconnected, and the operation is also complicated; fourthly, the extracted waste blood is often extracted in a needle cylinder and cannot be collected well in a centralized way; fifthly, the whole cost of manpower and material resources is high, the preparation time is long, the process is complicated, and the stability of the hemodynamics of the children patients cannot be ensured.
The general process of neonatal exchange is: the infant patient generally establishes two venous pathways, one arterial pathway, the arterial pathway and the venous pathway are not on the same side, the first venous pathway is used for infusing blood products, the second venous pathway is used for infusing maintenance liquid containing sugar, and the arterial pathway is used for drawing blood; the whole blood and the plasma need to be alternately infused according to a certain proportion, the speed of vein entry and the speed of artery exit are consistent, the balance of the blood system of the child patient is ensured, and the risk of sodium citrate poisoning is caused due to the infusion of a large amount of stock blood, so that the blood coagulation function of the child patient is abnormal, and therefore the calcium agent and the sodium citrate can be infused into the second vein for antagonism; when blood is drawn from the infant at the arterial end, the blood is easy to coagulate in the pipeline, so heparin sodium is additionally added for anticoagulation, and the pipeline is prevented from being blocked.
Disclosure of Invention
The utility model aims to provide a newborn blood changing system, which can integrate equipment used in the newborn blood changing process into one system, realize the automation of the blood changing process, reduce the manpower consumption, reduce the material cost and reduce the risk of blood infection in the blood specimen detection process.
In order to achieve the purpose of the utility model, the technical scheme adopted by the utility model is as follows: a newborn blood exchange system comprises a blood conveying pipeline, a blood pumping pipeline and a control display unit;
the blood transfusion pipeline comprises a first pipeline for conveying whole blood and a second pipeline for conveying plasma, one end of the first pipeline is communicated with a whole blood bag, one end of the second pipeline is communicated with a plasma bag, the other end of the first pipeline is joined with the other end of the second pipeline and then connected into a first vein, a first blood pump is arranged between one end and the other end of the first pipeline, and a second blood pump is arranged between one end and the other end of the second pipeline;
the blood drawing pipeline comprises a third pipeline, one end of the third pipeline is connected into an artery, the other end of the third pipeline is communicated with a waste blood bag, a silica gel blood collecting port, a heparin sodium anticoagulant injection port and a third blood pump are sequentially arranged between one end and the other end of the third pipeline, and the heparin sodium anticoagulant injection port is communicated to a first micro pump for injecting heparin sodium anticoagulant through a fourth pipeline;
a second micro pump for injecting a maintenance liquid into a second vein;
the first blood pump, the second blood pump, the third blood pump, the first micro pump and the second micro pump are controlled by the control display unit in a centralized mode.
In the above technical solution, the control display unit includes a display module, a key input module, and a central control module.
In the above technical scheme, a first bubble filter is arranged between one end of the first pipeline and the first blood pump.
In the above technical scheme, a second bubble filter is arranged between one end of the second pipeline in the second pipeline and the second blood pump.
In the above technical scheme, the other end of the first pipeline and the other end of the second pipeline are converged by the first three-way pipe.
In the above technical solution, a third bubble filter is disposed in the third pipeline between the heparin sodium anticoagulant injection port and the third blood pump.
In the above technical solution, the fourth pipeline is communicated to the third pipeline through a second three-way pipe.
In the technical scheme, the first blood pump, the second blood pump and the third blood pump are respectively provided with a bubble monitoring module, a flow monitoring module and a heating module.
In the above technical scheme, the first blood pump, the second blood pump and the third blood pump are all provided with temperature monitoring modules corresponding to the heating modules.
Due to the application of the technical scheme, compared with the prior art, the utility model has the following advantages:
1. according to the utility model, the devices used in the process of changing the blood of the newborn are integrated into one system, and the blood pumps and the micropumps are controlled in a centralized manner by controlling the display unit, so that the automation of the process of changing the blood is realized, the labor consumption is reduced, and the material cost is reduced;
2. the third pipeline of the utility model is provided with the silica gel blood sampling port, so that the syringe can be used for repeatedly puncturing and sampling blood, the operation is convenient, and the pollution probability caused by the blood sampling by disconnecting the pipeline is reduced.
Drawings
Fig. 1 is a system configuration diagram according to a first embodiment of the present invention.
Fig. 2 is a block diagram of a control structure according to a first embodiment of the present invention.
Wherein: 1. a first pipeline; 2. a second pipeline; 3. a whole blood bag; 4. a plasma bag; 5. a first vein; 6. a first blood pump; 7. a second blood pump; 8. a third pipeline; 9. an artery; 10. a waste blood bag; 11. a silica gel blood collection port; 12. heparin sodium anticoagulant injection port; 13. a third blood pump; 14. a fourth pipeline; 15. a first micro pump; 16. a second vein; 17. a second micro pump; 18. a first bubble filter; 19. a second bubble filter; 20. a first three-way pipe; 21. a third bubble filter; 22. a second three-way pipe.
Detailed Description
The utility model is further described with reference to the following figures and examples:
the first embodiment is as follows:
referring to fig. 1, the utility model provides a system for changing blood for a newborn, comprising a blood conveying pipeline, a blood pumping pipeline and a control display unit;
the blood transfusion pipeline comprises a first pipeline 1 for conveying whole blood and a second pipeline 2 for conveying plasma, one end of the first pipeline is communicated with a whole blood bag 3, one end of the second pipeline is communicated with a plasma bag 4, the other end of the first pipeline is connected into a first vein 5 after being converged with the other end of the second pipeline, a first blood pump 6 is arranged between one end and the other end of the first pipeline, and a second blood pump 7 is arranged between one end and the other end of the second pipeline;
the blood drawing pipeline comprises a third pipeline 8, one end of the third pipeline is connected into an artery 9, the other end of the third pipeline is communicated with a waste blood bag 10, a silica gel blood collection port 11, a heparin sodium anticoagulant injection port 12 and a third blood pump 13 are sequentially arranged between one end and the other end of the third pipeline, and the heparin sodium anticoagulant injection port is communicated with a first micro pump 15 for injecting heparin sodium anticoagulant through a fourth pipeline 14;
a second micropump 17 for injecting a maintenance fluid into the second vein 16;
the first blood pump, the second blood pump, the third blood pump, the first micro pump and the second micro pump are controlled in a centralized mode through the control display unit.
In this embodiment, the whole blood bag, the plasma bag and the waste blood bag are all detachable connection modes, and the specific connection mode is a current clinical common mode and is not described herein.
The micro pump used in the utility model is a novel pump force instrument which can accurately, micro, uniformly and continuously output a small amount of fluid and consists of a controller (namely, a control display unit in the utility model), an actuating mechanism and an injector. The throughput rate of the micropump is at most 99.9ml/h and at least 0.1ml/h, calculated as milliliters per hour. Therefore, the detailed structure of the micropump is not described herein since it is well known to those skilled in the art.
In this embodiment, the control display unit includes a display module, a key input module, and a central control module. The display module displays related parameters, the security inspection input module sets related functional parameters, and the central control module plays a role in control, and is usually an MCU controller.
In this embodiment, a first bubble filter 18 is disposed in the first pipeline between one end of the first pipeline and the first blood pump.
In this embodiment, a second bubble filter 19 is disposed in the second pipeline between one end of the second pipeline and the second blood pump.
In this embodiment, the other end of the first pipe and the other end of the second pipe are joined by a first tee 20.
In this embodiment, a third bubble filter 21 is disposed in the third pipeline between the heparin sodium anticoagulant injection port and the third blood pump.
In this embodiment, the fourth pipeline is communicated to the third pipeline through a second three-way pipe 22, wherein the heparin sodium anticoagulant injection port is one of the pipe orifices of the second three-way pipe.
In this embodiment, the first blood pump, the second blood pump and the third blood pump are all provided with a bubble monitoring module, a flow monitoring module and a heating module. Controlling whether the bubble filter works or not by monitoring the quantity of bubbles; the flow delivered by the blood pump is controlled by monitoring the flow; the blood conveyed by the blood pump is heated by the heating module to reach a comfortable temperature.
Furthermore, all be provided with the temperature monitoring module that corresponds heating module among first blood pump, the second blood pump and the third blood pump, realize the real time monitoring of blood temperature through setting up temperature monitoring module to ensure that blood can carry with constant temperature.
The control display unit of the utility model can set the speed and the blood exchange amount of each pump, can preset the infusion proportion of whole blood and plasma, can automatically switch the infusion of whole blood and plasma in the blood exchange process, automatically count the input amount of whole blood and plasma and the blood extraction amount, and can also set the reserved blood transfusion amount, namely, the blood extraction is stopped before the blood exchange is finished, and the blood transfusion is not stopped, thereby achieving the purpose of blood transfusion.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to the above-described embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the utility model. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (9)
1. A system for changing blood in a newborn infant, comprising: comprises a blood conveying pipeline, a blood pumping pipeline and a control display unit;
the blood transfusion pipeline comprises a first pipeline for conveying whole blood and a second pipeline for conveying plasma, one end of the first pipeline is communicated with a whole blood bag, one end of the second pipeline is communicated with a plasma bag, the other end of the first pipeline is joined with the other end of the second pipeline and then connected into a first vein, a first blood pump is arranged between one end and the other end of the first pipeline, and a second blood pump is arranged between one end and the other end of the second pipeline;
the blood drawing pipeline comprises a third pipeline, one end of the third pipeline is connected into an artery, the other end of the third pipeline is communicated with a waste blood bag, a silica gel blood taking port, a heparin sodium anticoagulant injection port and a third blood pump are sequentially arranged between one end and the other end of the third pipeline, and the heparin sodium anticoagulant injection port is communicated to a first micro pump for injecting heparin sodium anticoagulant through a fourth pipeline;
a second micro pump for injecting a maintenance liquid into a second vein;
the first blood pump, the second blood pump, the third blood pump, the first micro pump and the second micro pump are controlled in a centralized mode through the control display unit.
2. The neonatal exchange system of claim 1, wherein: the control display unit comprises a display module, a key input module and a central control module.
3. The neonatal exchange system of claim 1, wherein: a first bubble filter is arranged between one end of the first pipeline and the first blood pump.
4. The neonatal exchange system of claim 1, wherein: and a second bubble filter is arranged between one end of the second pipeline in the second pipeline and the second blood pump.
5. The neonatal exchange system of claim 1, wherein: the other end of the first pipeline and the other end of the second pipeline are converged by a first three-way pipe.
6. The neonatal exchange system of claim 1, wherein: and a third bubble filter is arranged between the heparin sodium anticoagulant injection port and a third blood pump in the third pipeline.
7. The neonatal exchange system of claim 1, wherein: the fourth pipeline is communicated to the third pipeline through a second three-way pipe.
8. The neonatal exchange system of claim 1, wherein: and the first blood pump, the second blood pump and the third blood pump are respectively provided with a bubble monitoring module, a flow monitoring module and a heating module.
9. The neonatal exchange system of claim 8, wherein: and the first blood pump, the second blood pump and the third blood pump are respectively provided with a temperature monitoring module corresponding to the heating module.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202120171848.6U CN216496772U (en) | 2021-01-21 | 2021-01-21 | Newborn blood exchange system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202120171848.6U CN216496772U (en) | 2021-01-21 | 2021-01-21 | Newborn blood exchange system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN216496772U true CN216496772U (en) | 2022-05-13 |
Family
ID=81460282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202120171848.6U Expired - Fee Related CN216496772U (en) | 2021-01-21 | 2021-01-21 | Newborn blood exchange system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN216496772U (en) |
-
2021
- 2021-01-21 CN CN202120171848.6U patent/CN216496772U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180235523A1 (en) | Bodily fluid monitoring system | |
| WO2012152200A1 (en) | Infusion monitoring system and method, nurse station management center | |
| CN110694132B (en) | Medical lavage system | |
| CN205586239U (en) | Disposable xiLin bottle dissolves medicine dispenser | |
| CN201320318Y (en) | Hemodialysis machine with weighing system for controlling ultrafiltration | |
| CN202490257U (en) | Intelligent automatic flushing device for infusion pipeline | |
| CN112717218A (en) | Newborn blood exchange system | |
| CN216496772U (en) | Newborn blood exchange system | |
| CN213158445U (en) | Multichannel automatic control's novel transfer pump | |
| JP4879440B2 (en) | Extracorporeal small volume treatment system | |
| CN209437777U (en) | A kind of sequential infusion device | |
| CN103170024B (en) | Normovolemic dilution autoblood collection and reinfusion system, and normovolemic dilution autoblood collection and reinfusion device | |
| CN108815602A (en) | A kind of Nephrology dept.'s clinical blood dialysis apparatus | |
| CN203139210U (en) | Portable system for monitoring infusion of extracorporeal circulation sodium citrate anticoagulant | |
| CN205796151U (en) | A kind of micro-injection pump of remote alarms | |
| CN110124134B (en) | Ascites ultrafiltration concentration therapeutic instrument | |
| CN205386253U (en) | Bioartificial liver on -line monitoring and integrative system of constant temperature heating | |
| CN113975510A (en) | Supplementary testing arrangement of tubulation of continuity kidney replacement therapy | |
| CN203555999U (en) | Safe and intelligent double-security infusion apparatus | |
| CN203763562U (en) | Recovering, concentrating, temperature-adjusting filtration system of autologous blood | |
| CN115212388A (en) | Intelligent preoperative continuous infusion device | |
| CN209361502U (en) | A kind of intelligence intravenous infusion device | |
| CN219835948U (en) | Neonate blood product input connecting device | |
| CN221765211U (en) | System for evaluating service time of hemofilter | |
| CN221845637U (en) | Pairing plasma dialysis replacement device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220513 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |